|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZMYM6 |
Gene summary for ZMYM6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZMYM6 | Gene ID | 9204 |
| Gene name | zinc finger MYM-type containing 6 | |
| Gene Alias | Buster2 | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O95789 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9204 | ZMYM6 | HCC1_Meng | Human | Liver | HCC | 2.26e-25 | 5.01e-02 | 0.0246 |
| 9204 | ZMYM6 | HCC2_Meng | Human | Liver | HCC | 4.69e-15 | 6.88e-02 | 0.0107 |
| 9204 | ZMYM6 | HCC1 | Human | Liver | HCC | 2.36e-04 | 2.56e+00 | 0.5336 |
| 9204 | ZMYM6 | HCC2 | Human | Liver | HCC | 2.26e-13 | 2.98e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZMYM6 | SNV | Missense_Mutation | novel | c.3646N>C | p.Ile1216Leu | p.I1216L | O95789 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZMYM6 | SNV | Missense_Mutation | novel | c.1437N>C | p.Lys479Asn | p.K479N | O95789 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZMYM6 | SNV | Missense_Mutation | novel | c.114G>T | p.Gln38His | p.Q38H | O95789 | protein_coding | deleterious(0.02) | possibly_damaging(0.526) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| ZMYM6 | insertion | Frame_Shift_Ins | novel | c.1909_1910insA | p.Ile637AsnfsTer11 | p.I637Nfs*11 | O95789 | protein_coding | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | ||
| ZMYM6 | deletion | Frame_Shift_Del | novel | c.2459delN | p.Lys820SerfsTer4 | p.K820Sfs*4 | O95789 | protein_coding | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZMYM6 | insertion | Frame_Shift_Ins | novel | c.274_275insT | p.Cys92LeufsTer5 | p.C92Lfs*5 | O95789 | protein_coding | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZMYM6 | insertion | Frame_Shift_Ins | novel | c.2412_2413insT | p.Glu805Ter | p.E805* | O95789 | protein_coding | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | ||
| ZMYM6 | insertion | Frame_Shift_Ins | novel | c.2171_2172insA | p.Asn724LysfsTer2 | p.N724Kfs*2 | O95789 | protein_coding | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ZMYM6 | SNV | Missense_Mutation | rs750502313 | c.2968N>G | p.Tyr990Asp | p.Y990D | O95789 | protein_coding | tolerated_low_confidence(0.19) | benign(0.209) | TCGA-BC-A10S-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| ZMYM6 | SNV | Missense_Mutation | novel | c.3385N>C | p.Ser1129Arg | p.S1129R | O95789 | protein_coding | deleterious(0.01) | possibly_damaging(0.483) | TCGA-DD-AADQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |